Point/Counterpoint: The Case for Gilead

The Federal Drug Administration shocked the pharmaceutical maker and its shareholders when it rejected an expected blockbuster arthritis drug until more data about its effects was available.

VIEW IN BROWSER

📚 Weekend Reads | Sunday, Aug 23, 2020

Point/Counterpoint: The Case for Gilead

It's been a rough week for Gilead. The Federal Drug Administration shocked the pharmaceutical maker and its shareholders when it rejected an expected blockbuster arthritis drug until more data about its effects was available. Analysts said it could delay the drug, filgotinib, into next year. Gilead does have a promising Covid-19 treatment, remdesivir, that is expected to drive as much as $3.5 billion in revenue. And it has its HIV treatments that still make up the bulk of sales. But the short-term case for Gilead shares is hard to argue. Investing.com's Geoffrey Smith writes about the upside for Gilead, while Christiana Sciaudone explains the bear case. This is Point/Counterpoint.

Read Full Article

World Financial Markets

Here is how leading financial instruments performed in the past week:

S&P 500 (SPX) 3,397.16 45.27 (0.72%) Volatility Index (VIX) 22.54 3.61 (2.22%) Crude Oil Futures (CL) 42.34 1.57 (0.79%) Gold Future (GC) 1,947 108 (-0.14%) BTC/USD 11,593 966 (-2.8%)

Most Popular Analysis

Exclusive: RingCentral Becoming the Other Pandemic Communications Bet By Christiana Sciaudone Zoom Video Communications Inc (NASDAQ:ZM) may be the obvious Covid-19 winner on everyone's lips, but there's another communications bet you may be missing: RingCentral (NYSE:RNG).

Apple Faces 3 Challenges As It Hits $2-Trillion Market Value By Haris Anwar/Investing.com Large influential companies do not always seek to expand the appearance of their power. It is something executives at Apple (NASDAQ:AAPL) might be thinking about as the iPhone-maker grabbed global...

Gold's $2,000 Comeback Slowed By Logic-Defying Dollar Strength By Barani Krishnan/Investing.com Back in June, even the naysayers would have privately admitted that they expected gold to hit $2,000 an ounce at some point this year, if not next. What even the bulls didn't anticipate was it getting...

As Indices Rise To Records, More And More Individual Stocks Sink By Michael Kramer This article was written exclusively for Investing.com The S&P 500 advanced to a record close on Aug. 18, completely erasing the March sell-off. But, despite the appearance of a healthy stock market,...

No Matter The U.S. Election Outcome, These 2 ETFs Will Benefit By Tezcan Gecgil/Investing.com Since early spring, broader equity markets in the US have been charging ahead. On Aug. 18, the S&P 500 index closed at 3,389.78, above its previous peak of 3,386.15 in February. So far in the...

Show More Analysis »

Download Our Award Winning Apps

Follow us:

To ensure proper delivery of Investing.com Newsletters to your inbox, please add newsletter@investingmail.com to your safe sender list.

Disclaimer: Fusion Media or anyone involved with Fusion Media will not accept any liability for any trading loss or damage as a result of reliance on the information contained within this email including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Fusion Media would like to remind you that the data contained in this email is neither necessarily real-time nor accurate. All stock prices, Indexes, Futures, buy/sell Signals and Forex prices are indicative and not appropriate for trading purposes; furthermore they are not provided by an exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price. Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. This is a newsletter from Investing.com © 2007-2020 Fusion Media Limited. All Rights Reserved 7 Florinis Street, Greg Tower 6th Floor Nicosia 1065 Cyprus Terms And Conditions   |   Privacy Policy   |   Manage your e-mail preferences   |   Unsubscribe This email was sent to o354397655@gmail.com